Phase II study of N-methylformamide, spi
โ
Ettinger, David S. ;Finkelstein, Dianne M. ;Donehower, Ross C. ;Chang, Alex Y. C
๐
Article
๐
1989
๐
John Wiley and Sons
๐
English
โ 407 KB
One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with s